SLS Overview

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sellas Life Sciences Group Inc revenue for the last quarter amounts to 0.00 USD, decreased

Sellas Life Sciences Group Inc. EPS for the last quarter amounts to -0.05 USD, decreased -44.44

Sellas Life Sciences Group Inc (SLS) has 13 emplpoyees as of May 12 2026.

Today SLS has the market capitalization of 968.80M USD.